scholarly journals Influence of autoimmune biomarkers on interstitial lung diseases: A tertiary referral center based case-control study

2015 ◽  
Vol 109 (3) ◽  
pp. 397-405 ◽  
Author(s):  
Philippe R. Bauer ◽  
Sanjay Kalra ◽  
Thomas G. Osborn ◽  
Jennifer St. Sauver ◽  
Andrew C. Hanson ◽  
...  
Keyword(s):  
Lung Diseases ◽  
Case Control Study ◽  
Case Control ◽  
Interstitial Lung Diseases ◽  
Tertiary Referral ◽  
Tertiary Referral Center ◽  
Referral Center ◽  
Control Study

Antiphospholipid antibodies may be associated with uveitis

2020 ◽  
pp. 112067212096872
Author(s):  
Yinon Shapira ◽  
Yael Ben-Arie-Weintrob ◽  
Boris Gilburd ◽  
Sandra Reuter ◽  
María Sánchez-Castañón ◽  
...  
Keyword(s):  
Antiphospholipid Antibodies ◽  
Case Control Study ◽  
Case Control ◽  
Healthy Controls ◽  
Tertiary Referral ◽  
Tertiary Referral Center ◽  
Nuclear Antigens ◽  
Infectious Uveitis ◽  
Unselected Population ◽  
Control Study

Purpose: To evaluate the prevalence of a spectrum of autoantibodies in adult patients with non-infectious uveitis compared to healthy controls. Methods: This is a case-control study conducted in a tertiary referral center. Serum positivity to auto-antibodies directed at membranous phospholipids (aPL), nuclear antigens, and cytoplasmic (ANCA) antigens were assessed in sera from 63 non-infectious uveitis patients, and 78 healthy controls. Uveitis patients’ demographic and clinical data were collected retrospectively from their medical charts. Results: Of the spectrum of antibodies evaluated only aPL were linked with uveitis (OR 11.2, CI 1.4–92.1), as 13 (20.6%) uveitis patients were positive to at least one of the screened aPL, namely either anti-cardiolipin (aCL), anti-β2-glycoprotein (aβ2GPI), or anti-phosphatidylserine/prothrombin (aPS/PT). aCL antibodies were detected in 5/63 (7.9%) of uveitis patients and in none of controls ( p = 0.016). Positivity to either aCL or aβ2GPI was noted in 8/63 (12.7%) of uveitis patients and in 1 (1.3%) of the controls ( p = 0.011). Of the 13 uveitis patients positive to any of the aPL antibodies, 8 (62%) had exclusively anterior uveitis, 9 (69%) were idiopathic, and none had evidence of posterior vaso-occlusive involvement or systemic thrombotic manifestations. Conclusion: An association between aPL and uveitis among an unselected population of patients with no evidence of thrombosis or presence of the antiphospholipid syndrome was documented in this study. This link was observed, alike the general population of uveitis patients, mainly in patients with anterior eye inflammation. A possible interaction between aPL and uveitis, mediated by non-thrombotic mechanisms, requires further studies.

Establishing Urinary Leukotriene E4 as a Diagnostic Biomarker for Chronic Rhinosinusitis with Comorbid Asthma and Atopy

2019 ◽  
Vol 161 (5) ◽  
pp. 764-769 ◽  
Author(s):  
Griffin D. Santarelli ◽  
Kent K. Lam ◽  
Joseph K. Han
Keyword(s):  
Chronic Rhinosinusitis ◽  
Case Control Study ◽  
Medical Center ◽  
Case Control ◽  
Healthy Controls ◽  
Diagnostic Biomarker ◽  
Tertiary Referral ◽  
Cysteinyl Leukotriene ◽  
Inflammatory State ◽  
Control Study

Objective While urinary leukotriene E4 (uLTE4) is a validated biomarker for the cysteinyl leukotriene pathway, which is central to the pathophysiology of asthma, atopy, and chronic rhinosinusitis (CRS), the contributions of comorbid asthma and atopy to uLTE4 levels in various CRS subtypes have not been previously characterized. We sought to (1) identify reference values for uLTE4 in subjects with and without CRS and (2) determine how the presence of comorbid atopy and asthma affects uLTE4 levels in CRS. Setting Tertiary referral medical center. Subjects and Methods A prospective case-control study was conducted to compare uLTE4 levels between patients with CRS and healthy controls. Urinary LTE4 levels were measured by enzyme immunoassay and were adjusted for urinary creatinine concentrations (pg/mg Cr). Patients with CRS were stratified by the clinical comorbidities to determine normative uLTE4 values for patients with CRS with and without comorbid asthma or atopy. Results A total of 153 patients (mean age, 47.3; 47.1% female) were included in the study. Patients with CRS demonstrated significantly higher concentrations of uLTE4 than healthy controls (1652 vs 1065 pg/mg Cr, P = .032). Within the group of patients with CRS, comorbid asthma also individually correlated with elevated uLTE4 levels (1597 pg/mg Cr, P = .0098). Patients with CRS who did not have comorbid allergy and asthma, in contrast, did not have statistically higher uLTE4 levels than healthy controls (1142 pg/mg Cr, P = .61). Conclusion Urinary LTE4 serves as a noninvasive measure of the inflammatory state in CRS. Comorbid asthma and atopy contribute to elevated uLTE4 levels in CRS.

scholarly journals Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case–control study

2021 ◽  
Author(s):  
Benedikt Kowalski ◽  
Alan Valaperti ◽  
Pascal Bezel ◽  
Urs C. Steiner ◽  
Dieter Scholtze ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Diseases ◽  
Bronchoalveolar Lavage Fluid ◽  
Case Control Study ◽  
Lavage Fluid ◽  
Case Control ◽  
Healthy Individuals ◽  
Control Groups ◽  
Cross Sectional ◽  
Control Study

Abstract Purpose Immune-checkpoint inhibitors (ICI) present a new treatment for malignancies by boosting the immune system. This has led to a variety of immune-related adverse events, including ICI-associated pneumonitis (ICIaP). Diagnosis thereof is often challenging, and its pathogenesis has not yet been fully understood. The aim of this cross-sectional case–control study was to investigate cytokines in serum and bronchoalveolar lavage fluid (BALF) expressed in patients with ICIaP compared to controls consisting of healthy individuals, patients with lung cancer and patients with interstitial lung diseases (ILD) other than ICIaP. Methods From January 2018 until June 2019, 401 adult patients with various lung diseases were prospectively enrolled in a BALF- and serum biobank, called BALOTHEK. Of these, 12 patients were diagnosed with ICIaP (Pembrolizumab, Ipilimumab, or both, and Durvalumab) serving as case group. Subjects with one of three diagnosis groups from BALOTHEK, including lung cancer, ILD other than ICIaP, and healthy individuals, served as matched controls. The following 11 cytokines were simultaneously analyzed in BALF and serum of each study participant: interferon gamma, tumor necrosis factor alpha, interleukin (IL) 1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-12p70, IL-13 and IL-17A. This study was approved by the local ethic review committee (BASEC-ID 2017-02,307 and 2018-01,724). Results Absolute number and percentage of lymphocytes in BALF of patients with ICIaP were significantly higher compared to control groups. For the investigated cytokines in BALF, a significant increase of IL-6 level was shown for patients with ICIaP compared to control groups (p = 0.031, adjusted for multiple comparisons). Conclusion Cytokine profile assessed in BALF shows promising potential for facilitating diagnosis and understanding of pathophysiology of ICIaP. IL-6 may not only contribute to better understanding of pathophysiology but also herald therapeutic implications for Tocilizumab.

Sign in / Sign up

Export Citation Format

Share Document